TCF7L1

Overview

TCF7L1 (Transcription Factor 7 Like 1, also known as TCF3) encodes a member of the TCF/LEF family of transcription factors that are transcriptional effectors of the Wnt/beta-catenin signaling pathway. TCF7L1 can act as a transcriptional repressor and competes with beta-catenin-bound TCF factors to modulate Wnt target gene expression. In colorectal cancer, TCF7L1 was identified as the fusion partner in a recurrent NAV2-TCF7L1 gene fusion that disrupts its beta-catenin binding domain, potentially dysregulating Wnt pathway transcription.

Alterations observed in the corpus

  • Recurrent NAV2-TCF7L1 gene fusion identified in 3 of 276 colorectal cancer cases (TCGA CRC cohort); the fusion results in loss of the beta-catenin binding domain in TCF7L1, suggesting aberrant Wnt pathway regulation PMID:22810696

Cancer types (linked)

  • COAD: Recurrent NAV2-TCF7L1 fusion observed in colorectal adenocarcinoma; disruption of beta-catenin interaction domain implicates Wnt pathway dysregulation PMID:22810696

Co-occurrence and mutual exclusivity

  • NAV2: Fusion partner in NAV2-TCF7L1; NAV2 (Neuron Navigator 2) provides the 5’ portion of the fusion, while TCF7L1 contributes a truncated C-terminus lacking the beta-catenin binding domain PMID:22810696
  • TCF7L2: Paralogous TCF/LEF family member also altered in colorectal cancer (deleted/mutated in 12% of non-hypermutated cases); both genes converge on Wnt pathway dysregulation PMID:22810696

Therapeutic relevance

  • No direct therapeutic targeting data; disruption of beta-catenin-TCF7L1 interaction in fusion cases may inform Wnt pathway targeting strategies in colorectal cancer PMID:22810696

Open questions

  • Functional consequence of the NAV2-TCF7L1 fusion on Wnt target gene regulation has not been experimentally validated PMID:22810696
  • Frequency in larger colorectal cancer cohorts and clinical significance are unknown

Sources

This page was processed by entity-page-writer on 2026-05-06.